CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 12 enrolled
Drug / intervention
Ivermectin +1 moredrug
Likely dose
Ivermectin 150 mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03459794
NCT03459794Early Ph 1Completed
CompareCT.gov

The Effects of Ivermectin on Human Innate Immunity Against Filarial Parasites

University of Georgia·interventional·Posted Mar 9, 2018·Updated Jul 12, 2019

In Brief

A Early Phase 1 clinical trial evaluating Ivermectin and Placebo for Ivermectin. Completed, enrolled 12 participants across 1 site.

Detailed Summary

We hypothesize that ivermectin, a drug used to treat parasitic worm infections, interacts with the human innate immune system and that this contributes to its anti-parasitic effects. Participants will donate blood before and after being administered the normal human dose of the drug. We will compare the cell types present in the blood and the chemicals known to influence the human immune system before and after the drug is given, as well as measuring any changes in gene expression in white blood cells 4 and 24hrs after the drug is taken.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIvermectin
CountriesUnited States
Collaborators--

Timeline

Early Ph 1CompletedFinished
201820192020202120222023202420252026
First PostedMar 9, 2018
Enrollment StartFeb 12, 2018
Primary CompletionApr 9, 2018
Study CompletionNov 30, 2018
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 8.3 years ago

Interventions

Ivermectindrug

150 mcg/kg ivermectin, by mouth.

Placeboother

An oral placebo will be administered, once